Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertapenem versus high-dose levofloxacin in elderly patients with serious community-acquired bacterial pneumonia
2004-002988-24Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in community acquired pneumonia (CAP) comparing Ertapenem arm with High-dose levofloxacin arm (2 arms). Primary endpoints: Favorable clinical response at end of therapy and Favorable clinical response at test of cure. Started May 2005; status: completed.
02
Drugs
ertapenemlevofloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2004-002988-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002988-24.